Processa Pharmaceuticals Files 8-K on Security Holder Rights

TL;DR

Processa Pharma (PCSA) filed an 8-K on 12/15, reporting changes to security holder rights and corporate docs as of 12/12.

AI Summary

Processa Pharmaceuticals, Inc. filed an 8-K on December 15, 2025, reporting events as of December 12, 2025. The filing indicates material modifications to the rights of security holders and amendments to its articles of incorporation or bylaws. It also includes financial statements and exhibits.

Why It Matters

This 8-K filing signals potential changes affecting Processa Pharmaceuticals' security holders and corporate structure, requiring investor attention.

Risk Assessment

Risk Level: medium — Filings related to modifications of security holder rights and amendments to corporate documents can indicate significant strategic shifts or potential governance changes.

Key Players & Entities

• Processa Pharmaceuticals, Inc. (company) — Registrant
• 12/12/2025 (date) — Date of earliest event reported
• 001-39531 (other) — Commission file number
• Delaware (other) — State of incorporation
• 45-1539785 (other) — I.R.S. Employer Identification Number
• 601 21st Street, Suite 300 Vero Beach, FL 32960 (address) — Principal Executive Offices
• (772) 453-2899 (phone_number) — Registrant's phone number

FAQ

Key Financial Figures

• $0.0001 — nding shares of common stock, par value $0.0001 per share (the "Common Stock"), effecti

Filing Documents

• form8-k.htm (8-K) — 42KB
• ex3-1.htm (EX-3.1) — 8KB
• 0001493152-25-027680.txt ( ) — 218KB
• pcsa-20251212.xsd (EX-101.SCH) — 3KB
• pcsa-20251212_lab.xml (EX-101.LAB) — 33KB
• pcsa-20251212_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): 12/12/2025 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification Number) 601 21 st Street , Suite 300 Vero Beach , FL 32960 (Address of Principal Executive Offices, Including Zip Code) (772) 453-2899 (Registrant's Telephone Number, Including Area Code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered Common stock: Par value $.0001 PCSA Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 3.03 Material Modification to Rights of Security Holders To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference. Item 5.03 Amendments to articles of incorporation or bylaws; change in fiscal year On December 12, 2025, Processa Pharmaceuticals, Inc. (the "Company") filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the "Certificate of Amendment") to the Company's Fourth Amended and Restated Certificate of Incorporation to effect a 1-for-25 reverse stock split (the "Reverse Stock Split") of the Company's issued and outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"), effective as of 5:00 p.m. Eastern Time on December 16, 2025. Beginning with the opening of trading on December 17, 2025, Processa's Common Stock will trade on the Nasdaq Capital Market on a split-adjusted basis under new CUSIP number 74275C403 and will continue to trade under the symbol "PCSA." As a result of the Reverse Stock Split, every twenty-five (25) shares of Common Stock issued and outstanding will be converted into one (1) share of Common Stock. We will not be issuing fractional shares in connection with the Reverse Stock Split. Stockholders who otherwise would be entitled to receive fractional shares because they hold a number of shares not evenly divisible by the reverse stock split ratio of the Reverse Stock Split, will be entitled, upon surrender of certificate(s) representing these shares, to a number of shares rounded up to the nearest whole number and, accordingly, no money will be paid for a fractional share. The Reverse Stock Split will not reduce the number of authorized shares of Common Stock of 1,000,000,000 or change the par value of the Common Stock. The Reverse Stock Split will affect all stockholders uniformly and will not affect any stockholder's ownership percentage of the Company's shares of Common Stock except for the impact of fractional shares. All outstanding options, warrants, restricted stock units and similar securities entitling their holders to receive or purchase shares of Common Stock will be adjusted as a result of the Reverse Stock Split, as required by the terms of each security. The foregoing description of the Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Company is a summary of the material terms thereof, does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, which is filed with this report as Exhibit 3.1 and is incorporated herein by reference. Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Description 3.1 Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Company, effective December 16, 2025. 104 Cover Page Interactive Data File (formatted as Inline XBRL) SIGNATURE Pursu

View Full Filing

View this 8-K filing on SEC EDGAR